Understand the source comparison
Tesofensine for Women Over 40 Comparison
Tesofensine Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin) 9–11% at 0.5–1.0mg daily +10–15 bpm heart rate, +5–10 mmHg blood pressure Energy expenditure collapse, mood-driven eating, neurotransmitter depletion in metabolically resist
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine
- Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin)
- 9–11% at 0.5–1.0mg daily
- +10–15 bpm heart rate, +5–10 mmHg blood pressure
- Energy expenditure collapse, mood-driven eating, neurotransmitter depletion in metabolically resistant women
- Best suited for women without cardiovascular contraindications who've plateaued despite caloric restriction
- Semaglutide (GLP-1)
- GLP-1 receptor agonism, delayed gastric emptying
- 12–15% at 2.4mg weekly
- Minimal. Slight heart rate increase (~1–2 bpm)
- Portion control issues, high hunger between meals, insulin resistance
- Superior safety profile for women with hypertension or cardiovascular risk
- Orlistat
- Lipase inhibition (blocks fat absorption)
- 3–5% with dietary fat restriction
- None significant
- Patients requiring non-systemic option, high dietary fat intake
- Lowest efficacy but safest cardiovascular profile. Mechanism limits absorption, not metabolism
- Phentermine
- Norepinephrine release (sympathomimetic)
- 5–7% short-term
- +15–20 bpm heart rate, +10–15 mmHg blood pressure
- Short-term appetite suppression (12-week protocols)
- Higher cardiovascular impact than tesofensine with lower weight loss efficacy. Typically reserved for 3-month cycles